STOCKHOLM, Aug 5 (Reuters) – Novo Nordisk said on Wednesday it had won a preliminary injunction against Ceban Ziekenhuisfarmacie from a district court in the Netherlands in a patent infringement case involving a compounded semaglutide nasal spray.
Semaglutide is the active ingredient in Novo Nordisk’s weight-loss drug Wegovy.
“The Court found that Ceban infringed Novo Nordisk’s supplementary protection certificate (SPC) covering semaglutide,” the Danish drugmaker said in a statement.
It said the court ordered Dutch firm Ceban to cease the infringing activities, remove product listings, disclose supply chain information, and reimburse Novo Nordisk’s legal costs.
(Reporting by Anna Ringstrom, editing by Elviira Luoma)
